Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

The Lancet

Volumn 344, Issue 8934, 1994, Pages 1383-1389

  Scandinavian Simvastatin Survival Study Group, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SURVIVAL;

ADULT; AGED; ANGINA PECTORIS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SIMVASTATIN; SURVIVAL ANALYSIS;

EID: 0027987849     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90566-5     Document Type: Article

References (35)

1. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease
2. The Oslo Diet Heart Study: eleven-year report
3. Clofibrate and niacin in coronary heart disease
4. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid
5. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate
6. The Lipid Research Clinics coronary primary prevention trial results
7. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipemia
8. Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality
9. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia-report of the Program on the Surgical Control of Hyperlipidemias (POSCH)
10. Lowering blood cholesterol to prevent heart disease consensus conference
11. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society
12. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (adult treatment panel II)
13. Prevention of coronary heart disease in clinical practice Recommendations of the Task Force of the European Society of Cardiology European Atherosclerosis Society and European Society of Hypertension
14. Doubts about preventing coronary heart disease. Multiple interventions in middle aged men may do more harm than good
15. Should there be a moratorium on the use of cholesterol lowering drugs?
16. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
17. The value of lowering cholesterol after myocardial infarction
18. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome
19. Simvastatin, a review of its pharmacological properties and therapeutic potential in hypercholesterolemia
20. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin
21. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction
22. Acute myocardial infarction in Finland: baseline data from the FINMONICA AMI register in 1983-85
23. A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes
24. Regression methods of life tables (with discussion)
25. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study
26. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
27. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin
28. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
29. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
30. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
31. Retardation and arrest of progression or regression of coronary artery disease: a review
32. Prognostic significance of progression of coronary atherosclerosis
33. Atherosclerosis: inhibition or regression as therapeutic possibilities
34. The pathogenesis of coronary artery disease and acute coronary syndromes